Alliance Pharma (#APH) - FD to leave in May - looks like an orderly transition
- 2015-02-17 01:05:02
UK 06:34 Wednesday, 28 October 2026
Breaking news and expert analysis on fast-moving AIM and LSE listed shares
Speciality pharmaceutical company, Alliance Pharma (APH) has updated that 2014 “pre-tax profits are expected to be in line with current market expectations” on turnover of £43.5 million and that “we continue to evaluate a number of acquisition opportunities”.
Alliance Pharma (APH) last week announced results for the first half of the 2014 calendar year and that “we expect full year results to be in line with market expectations”. This makes the shares a buy at up to 35p
Alliance Pharma (APH) has updated investors attending its AGM that “trading in the first four months of 2014 has been in line with expectations” and that “we continue to work towards delivering further earnings enhancing acquisitions to outperform those plans”.
Direct from the Queen Elizabeth Conference Centre a video featuring a UK Investor Show 2014 presentation by John Dawson of Alliance Pharma (APH)
Alliance Pharma (APH) has announced that Nigel Wray has purchased a further 1.55 million shares in the company, taking his shareholding to 39,656,995 shares, 15.02% of the company's issued share capital.
Speciality pharmaceutical company, Alliance Pharma (APH) last week announced that “turnover for 2013 is expected to be £45.5m (2012: £44.9m) and pre-tax profits are expected to be in line with current market expectations” (expectations are for earnings per share of around 3.5p) as well as an acquisition of the rights to the thyroid product Irenat in Germany from subsidiaries of Bayer AG.
Shares in speciality pharmaceutical company Alliance Pharma (APH) trade at 35.25p-35.75p on the back of its results announcement for the first half of calendar 2013 which came out last week. Having been added to the Recovery portfolio on my Nifty Fifty website at a 31p offer price in December, we are ahead but not by as much as I would have hoped.
AIM-listed speciality pharmaceutical company Alliance Pharma (APH) has announced “trading in the first half of the year has been in line with management’s expectations” and that it “continues to explore a number of acquisition opportunities and remains confident of the outlook for the full year”. So is it a buy. Pushed for an answer I’d say yes.
Alliance Pharma (APH) is in the news today as it has announced an $11.5 million (£7.5 million) acquisition of all existing rights to the ‘Syntometrine’ drug from industry major Novartis
Specialty pharmaceutical company Alliance Pharma (APH) has today announced an $11.5 million (£7.5 million) acquisition of all existing rights to the ‘Syntometrine’ drug from industry major Novartis. This is part of its strategy of buying in “orphan” brands from majors which it can then monetize by flogging through its existing sales infrastructure.
AIM-listed speciality pharmaceutical company Alliance Pharma (APH) has updated that “trading in the first four months of 2013 has been 6% ahead of the same period last year (5% on an underlying basis), with turnover of £15.1 million”.
A new stock, of which star fund manager Mark Slater is a fan, has just been added to the Growth Portfolio on the 'Nifty Fifty' website which I write with Tom Winnifrith.
Alliance Pharma (APH), the speciality pharmaceutical company which acquires and licenses established products in niche areas, announced its calendar 2012 results a couple of weeks ago. The numbers contained no nasty shocks. That is no surprise, one of the great attractions of Alliance is that there is a real visibility of revenues. I tipped the shares on my premium Nifty Fifty service at 31p (offer price) in December and they now trade at 36-37p but are still a buy.
